COLO-COHORT (Colorectal Cancer Cohort) Study

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

This is a cross-sectional study aimed at identifying factors which best predicts patients at high risk of colorectal cancer or colorectal adenomas and to develop a risk prediction model.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Group A

• Aged ≥30 years\* and able to give informed consent

• Patients attending colonoscopy

‣ Through Bowel Cancer Screening Programme (FIT positive, Bowelscope conversion, surveillance)

⁃ Through standard NHS care (most commonly due to iron deficiency anaemia, altered bowel habit, weight loss, rectal bleeding, planned polypectomy\*\*, those referred on basis of family history, abnormal cross-sectional imaging, polyp surveillance or post CRC surveillance)

∙ The age of 30 was chosen to ensure that this is a population likely to be enriched for colorectal neoplasia with neoplasia below this age uncommon \*\*In those attending for planned polypectomy, the results from the initial colonoscopy and the endoscopy where the polypectomy is undertaken will be summated for purposes of calculating the neoplasia profile

• (COLO-SPEED) Group B

• Any patient attending for colonoscopy and able to give informed consent

• ≥ 18 years old

• Patient from the North of England

Locations
Other Locations
United Kingdom
Kettering General Hospitals NHS Foundation Trust
NOT_YET_RECRUITING
Kettering
South Tyneside and Sunderland NHS Foundation Trust
RECRUITING
South Shields
North Tees and Hartlepool NHS Foundation Trust
RECRUITING
Stockton-on-tees
Contact Information
Primary
Sara Koo
sara.koo@stft.nhs.uk
0191 404 1000
Backup
Amy Burns
Time Frame
Start Date: 2019-12-13
Estimated Completion Date: 2026-08-15
Participants
Target number of participants: 15000
Treatments
Group A (Cross-sectional arm)
This group will comprise of 10,000 patients who have been referred for a colonoscopy. We will be collecting information on their past medical history, smoking history, alcohol history, medication history and family history in addition to their colonoscopy findings. In 6000 of these patients, they will have blood tests, Faecal Immunochemical Test (FIT) level, blood or saliva for DNA extraction and stool microbiome taken. In 4000 of these patients, we will record recent blood tests of interest and they will have no new samples taken. All 10000 patients will also either complete a food frequency questionnaire or endoscopy patient experience questionnaire.
COLO-SPEED (Group B, consent for contact arm)
This will be 10,000 patients who will consent for future contact for future research studies.
Related Therapeutic Areas
Sponsors
Leads: South Tyneside and Sunderland NHS Foundation Trust
Collaborators: Newcastle University

This content was sourced from clinicaltrials.gov